Genentech files Avastin for new brain cancer use
This article was originally published in Scrip
Genentechhas filed its anti-VEGF monoclonal antibody Avastin (bevacizumab) in the US for use in patients with previously treated glioblastoma. The supplemental BLA is eligible for accelerated review based on preliminary evidence suggesting a clinical benefit for this aggressive cancer, and is based on data from the Phase II BRAIN study reported at ASCO earlier this year.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.